Development of a Human Skin Commensal Microbe for Bacteriotherapy of Atopic Dermatitis and Use in a Phase I Randomized Clinical Trial

The authors investigated the safety and mechanisms of action of Staphylococcus hominis A9, a bacterium isolated from healthy human skin, as a topical therapy for atopic dermatitis.
[Nature Medicine]
Nakatsuji, T., Hata, T. R., Tong, Y., Cheng, J. Y., Shafiq, F., Butcher, A. M., Salem, S. S., Brinton, S. L., Rudman Spergel, A. K., Johnson, K., Jepson, B., Calatroni, A., David, G., Ramirez-Gama, M., Taylor, P., Leung, D. Y. M., & Gallo, R. L. (2021). Development of a human skin commensal microbe for bacteriotherapy of atopic dermatitis and use in a phase 1 randomized clinical trial. Nature Medicine, 1–10. https://doi.org/10.1038/s41591-021-01256-2 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Understanding the Key Issues in the Treatment of Uncontrolled Persistent Asthma with Type 2 Inflammation

Researchers summarize the current understanding of the biology of type 2 inflammation in asthma, examine its influence on type 2 inflammatory comorbidities, and discuss how type 2 inflammatory biomarkers can be harnessed to further personalise treatments in the age of biologic medicines.
[European Respiratory Journal]
Busse, W. W., Kraft, M., Rabe, K. F., Deniz, Y., Rowe, P., Ruddy, M., & Castro, M. (2021). Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation. European Respiratory Journal. https://doi.org/10.1183/13993003.03393-2020 Cite
Abstract
Bookmark

No account yet? Register

0
Share

BELLUS Health Announces First Patient Dosed in its Phase II BLUEPRINT Trial of BLU-5937 for the Treatment of Chronic Pruritus Associated with Atopic Dermatitis

BELLUS Health Inc. announced that the first patient has been dosed in the Phase II BLUEPRINT trial of BLU-5937, the company’s highly selective P2X3 antagonist, in patients with chronic pruritus associated with atopic dermatitis.
[BELLUS Health Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

RINVOQ (upadacitinib) Achieved Superiority Versus DUPIXENT® (dupilumab) for Primary and All Ranked Secondary Endpoints in Phase IIIb Head-to-Head Study in Adults with Atopic Dermatitis

AbbVie announced top-line results from the Phase IIIb Heads Up study showing that upadacitinib achieved superiority to dupilumab for the primary endpoint, the proportion of patients with at least a 75% improvement in the Eczema Area Severity Index at week 16, in adults with moderate to severe atopic dermatitis.
[AbbVie (PR Newswire, LLC)]
Press Release
Bookmark

No account yet? Register

0
Share

High-Density Lipoprotein (HDL) in Allergy and Skin Diseases: Focus on Immunomodulating Functions

The authors summarize the newly identified changes in the metabolism, composition, and function of HDL in allergies and skin diseases. They also highlight the possible pathophysiological consequences with a focus on HDL-mediated immunomodulatory activities.
[Biomedicines]
Trakaki, A., & Marsche, G. (2020). High-Density Lipoprotein (HDL) in Allergy and Skin Diseases: Focus on Immunomodulating Functions. Biomedicines, 8(12), 558. https://doi.org/10.3390/biomedicines8120558 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Adipokines in the Skin and in Dermatological Diseases

Investigators provide an overview on how adipokines may integrate into the physiological conditions of the skin by introducing the cell types which are known to produce adipokines as well as the signals that target them. They also discuss data from in vivo and in vitro murine and human studies as well as genetic data on how adipokines may contribute to various aspects of the homeostasis of the skin just as to the pathogenesis of dermatological diseases.
[International Journal of Molecular Sciences]
Kovács, D., Fazekas, F., Oláh, A., & Törőcsik, D. (2020). Adipokines in the Skin and in Dermatological Diseases. International Journal of Molecular Sciences, 21(23), 9048. https://doi.org/10.3390/ijms21239048 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Evelo Biosciences Completes Enrollment to Interim Target in Phase II Trial Evaluating EDP1815 for the Treatment of Psoriasis

Evelo Biosciences, Inc. announced that it is recruiting ahead of schedule and has completed enrollment of the patients necessary for the interim data readout in the Phase II clinical trial evaluating EDP1815 for the treatment of mild to moderate psoriasis. The interim data readout includes initial safety and efficacy data for the first 113 patients enrolled in the trial.
[Evelo Biosciences, Inc. (Globe Newswire, Inc)]
Press Release
Bookmark

No account yet? Register

0
Share

Dupixent® (Dupilumab) Approved by European Commission as First and Only Biologic Medicine for Children Aged 6 to 11 Years with Severe Atopic Dermatitis

The European Commission extended the marketing authorization for Dupixent® in the European Union (EU) to include children 6 to 11 years of age with severe atopic dermatitis who are candidates for systemic therapy. Dupixent® is the only systemic medicine approved in the EU to treat these patients.
[European Commission (Globe Newswire Inc.)]
Press Release
Bookmark

No account yet? Register

0
Share

Role of 11β-Hydroxysteroid Dehydrogenase Type 1 in the Development of Atopic Dermatitis

Researchers assessed whether 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1) affected the development of atopic dermatitis (AD) in vitro and in vivo. The expression of 11β-HSD1 in the epidermis of AD lesions was higher than that in the epidermis of healthy controls.
[Scientific Reports]
Fernández-Calle, R., Galán-Llario, M., Gramage, E., Zapatería, B., Vicente-Rodríguez, M., Zapico, J. M., de Pascual-Teresa, B., Ramos, A., Ramos-Álvarez, M. P., Uribarri, M., Ferrer-Alcón, M., & Herradón, G. (2020). Role of RPTPβ/ζ in neuroinflammation and microglia-neuron communication. Scientific Reports, 10(1), 20259. https://doi.org/10.1038/s41598-020-76415-5 Cite
Full Article
Bookmark

No account yet? Register

0
Share

FDA Grants Priority Review and EMA Accepts Regulatory Submission for Pfizer’s Abrocitinib, an Oral Once-Daily JAK1 Inhibitor, for Patients 12 and Up with Moderate to Severe Atopic Dermatitis

Pfizer Inc. announced that the FDA accepted for filing and granted Priority Review designation to the company’s New Drug Application for abrocitini, an investigational oral once-daily Janus kinase 1 inhibitor, for the treatment of moderate to severe atopic dermatitis in patients 12 and older.
[Pfizer Inc. (BusinessWire, Inc.)]
Press Release
Bookmark

No account yet? Register

0
Share

CHMP Recommends Approval of Dupixent® (Dupilumab) for Children Aged 6 to 11 Years with Severe Atopic Dermatitis

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Dupixent®, recommending to extend the approval in the European Union to include children aged 6 to 11 years with severe atopic dermatitis who are candidates for systemic therapy.
[CHMP (Globe Newswire LLC)]
Press Release
Bookmark

No account yet? Register

0
Share
Share